Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials

Alzheimer Disease and Associated Disorders

Volumn 23, Issue 3, 2009, Pages 260-267

  Schneider, Lon S ^a   Raman, Rema ^b   Schmitt, Frederick A ^c   Doody, Rachelle S ^d   Insel, Philip ^b   Clark, Christopher M ^e   Morris, John C ^f   Reisberg, Barry ^g   Petersen, Ronald C ^h   Ferris, Steven H ^g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h MAYO CLINIC   (United States)

Author keywords

Alzheimer disease; Clinical trials; Dementia; Donepezil; Global impression of change; Mild cognitive impairment; Rating scales; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; DONEPEZIL; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; BECK DEPRESSION INVENTORY; BRAIN FUNCTION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTRUCT VALIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DISEASE SEVERITY; EDUCATIONAL STATUS; EXTERNAL VALIDITY; FEASIBILITY STUDY; HUMAN; MAJOR CLINICAL STUDY; MEMORY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; QUALITY OF LIFE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; INDANS; MEMORY; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; VITAMIN E;

EID: 70349155504     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31819cb760     Document Type: Article

References (20)

1. Schneider LS, Clark C, Doody R, et al. ADCS Prevention Instrument Project: ADCS-clinician's global impression of change scales (ADCS-CGIC), self-rated and study partnerrated versions. Alzheimer Dis Assoc Disord. 2006;20:124-138.
2. Leber P. What is the evidence that a dementia treatment works? Criteria used by drug regulatory authorities. In: Qizilbash N, Schneider LS, Chui HC, et al, eds. Evidence-Based Dementia Practice. Oxford, UK: Blackwell; 2003:376-387.
3. Schneider LS, Olin JT, Doody RS, et al, and the Alzheimer's Disease Cooperative Study. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997;11(suppl 2): S22-S32.
4. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
5. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352:2379-2388.
6. Folstein MF, Folstein SE, McHugh PR. ''Mini-mental state''. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
7. Mohs RC. The Alzheimer's disease assessment scale. Int Psychogeriatr. 1996;8:195-203.
8. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13-S21.
9. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11:33S-39S.
10. Galasko D, Bennett DA, Sano M, et al. ADCS prevention instrument project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord. 2006;20:S152-S159.
11. Reisberg B, Ferris SH, de Leon MJ, et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136-1139.
12. Patterson MB, Whitehouse PJ, Edland SD, et al. ADCS Prevention Instrument Project: quality of life assessment (QOL). Alzheimer Dis Assoc Disord. 2006;20:S179-S190.
13. Hochberg Y. A sharper Bonferroni procedure for multiple tests of signi.cance. Biometrika. 1988;75:800-802.
14. Salloway S, Ferris S, Kluger A, et al. E.cacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004;63:651-657.
15. Stern Y, Albert S, Tang MX, et al. Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology. 1999;53:1942-1947.
16. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59-66.
17. Fleisher AS, Sowell BB, Taylor C, et al, for the Alzheimer's Disease Cooperative Study. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007;68:1588-1595.
18. Hedeker D, Gibbons R. Longitudinal Data Analysis. Hoboken: John Wiley & Sons, Inc; 2006.
19. Winship C, Mare RD. Regression models with ordinal variables. Am Sociol Rev. 1984;49:512-525.
20. Olin JT, Schneider LS, Doody RS, et al. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. J Geriatr Psychiatry Neurol. 1997;9:176-180.